Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Neovascular Age-Related Macular Degeneration (nAMD) Clinical Trials

4 recruiting trials for Neovascular Age-Related Macular Degeneration (nAMD). Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
2
Phase 3 Trials
4
Sponsors

Recruiting Trials

RECRUITINGPhase 1 / Phase 2NCT05769153

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular...

Sponsor: Alcon ResearchEnrolling: 14020 locations
RECRUITINGPhase 3NCT06856577

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular...

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with...

Sponsor: Adverum Biotechnologies, Inc.Enrolling: 28420 locations
RECRUITINGEarly Phase 1NCT06031727

CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration...

Age-related macular degeneration (AMD) is a progressive disease leading to severe and irreversible vision loss of which the neovascular AMD (nAMD) accounted for 90% blindness in...

Sponsor: HuidaGene Therapeutics Co., Ltd.Enrolling: 122 locations
RECRUITINGPhase 3NCT07317934

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular...

Sponsor: Innostellar Biotherapeutics Co.,LtdEnrolling: 33220 locations